

REPROS THERAPEUTICS INC.  
Form 8-K  
June 07, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**Current Report Filed Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

**Date of Report**

**(Date of earliest event reported): June 7, 2016**

**Repros Therapeutics Inc.**

**(Exact name of registrant as specified in its charter)**

<b>Delaware</b>	<b>001-15281</b>	<b>76-0233274</b>
<b>(State or other jurisdiction of incorporation or organization)</b>	<b>(Commission File Number)</b>	<b>(I.R.S. Employer Identification No.)</b>

**2408 Timberloch Place, Suite B-7**

**The Woodlands, Texas 77380**

**(Address of principal**

**executive offices**

**and zip code)**

**(281) 719-3400**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

The information in this Current Report is being furnished pursuant to Item 7.01 of Form 8-K and, according to general instruction B.2. thereunder, the information in this Current Report shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended.

Representatives of Repros Therapeutics Inc., a Delaware corporation (the “Company”) are presenting updates on the Company’s Enclomiphene and Proellex® clinical programs at the 2016 BIO International Convention, and to various investors and other interested parties June 7 through June 8, 2016, using slides containing the information attached to this Current Report on Form 8-K as Exhibit 99.1. These slides contain statements that are “forward-looking statements” subject to the cautionary statement about forward-looking statements set forth therein.

**Item 9.01 Financial Statements and Exhibits.**

Exhibit

NumberDescription

99.1 Repros Therapeutics Slideshow

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934 the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Repros Therapeutics Inc.**

Date: June 7, 2016

By: /s/ Kathi Anderson  
Kathi Anderson  
Chief Financial Officer

**EXHIBIT INDEX**

Exhibit  
NumberDescription

99.1 Repros Therapeutics Slideshow